Showing 7171-7180 of 8649 results for "".
- First Patient Dosed in Ocugen's Phase 1/2 Trial Evaluating Safety and Efficacy of OCU41OST Modifier Gene Therapy for Stargardt Diseasehttps://modernod.com/news/first-patient-dosed-in-ocugens-phase-12-trial-evaluating-safety-and-efficacy-of-ocu41ost-modifier-gene-therapy-for-stargardt-disease/2481960/Ocugen announced that the first patient has been dosed in its phase 1/2 GARDian clinical trial for OCU410ST (AAV5-hRORA)—a modifier gene therapy candidate being developed for Stargardt disease. “There is a significant unmet medical need for the approximate 35,000 patien
- IRIS Registry-based Study Evaluates Side-Effect of Semaglutide Weight-Loss Drug on Diabetic Retinopathyhttps://modernod.com/news/iris-registry-based-study-evaluates-side-effect-of-semaglutide-weight-loss-drug-on-diabetic-retinopathy/2481947/According to the American Academy of Ophthalmology (AAO), new review of real-world data offers reassurance for the use of the diabetes drug semaglutide, which is popular for helping people lower their glucose levels and better manage their weight. At issue has been that a potential side effect of
- Belite Bio’s Tinlarebant Studied to Treat Childhood-onset Stargardt Diseasehttps://modernod.com/news/belite-bios-tinlarebant-studied-to-treat-childhood-onset-stargardt-disease/2481950/Belite Bio presented final data from a 24-month, phase 2 study of Tinlarebant (LBS-008) in adolescent Stargardt disease (STGD1). The study—LBS-008-CT02—enrolled 12 adolescent STGD1 patients, aged 12-18 years, who completed
- GATHER2 Study Shows Izervay Monthly or Every Other Month Reduced GA Lesion Growth Through 2 Yearshttps://modernod.com/news/gather2-study-shows-izervay-monthly-or-every-other-month-reduced-ga-lesion-growth-through-2-years/2481944/Astellas Pharma announced results from the GATHER2 phase 3 clinical trial, demonstrating Izervay (avacincaptad pegol intravitreal solution) continued to reduce the rate of geographic atrophy (GA) lesion growth for both every month (EM) and every-other-month (EOM) dosing vs. sham through
- GALE Extension Study Shows Syfovre Continued to Demonstrate Increasing Treatment Effects Over 3 Years in Patients with GAhttps://modernod.com/news/gale-extension-study-shows-syfovre-continued-to-demonstrate-increasing-treatment-effects-over-3-years-in-patients-with-ga/2481943/Apellis Pharmaceuticals announced data from the GALE extension study following 3 years of continuous treatment with Syfovre (pegcetacoplan injection), the first FDA-approved treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The data were rep
- Verana Health Partners with Foundation Fighting Blindness to Integrate Genetic Testing Data into Real-World Evidence Researchhttps://modernod.com/news/verana-health-partners-with-foundation-fighting-blindness-to-integrate-genetic-testing-data-into-real-world-evidence-research/2481940/Verana Health and the Foundation Fighting Blindness announced a partnership focused on providing the life sciences community with deeper and broader data to optimize and expedite clinical trials. Under the partnership, the Foundation will provide Verana with de-identified genomics
- SpyGlass Pharma Initiates Phase 1/2 Clinical Trial of its Intraocular Drug Delivery Platformhttps://modernod.com/news/spyglass-pharma-initiates-phase-12-clinical-trial-of-its-intraocular-drug-delivery-platform/2481924/SpyGlass Pharma announced the initiation of a phase 12 clinical trial investigating its intraocular drug delivery platform in patients with glaucoma and visually significant cataracts. The SpyGlass
- Oertli Opens New Lean Factory Building in Berneck, Eastern Switzerlandhttps://modernod.com/news/oertli-opens-new-lean-factory-building-in-berneck-eastern-switzerland/2481922/Oertli Instrumente recently celebrated the opening of its new Lean Factory building at its main site in Berneck, Eastern Switzerland. The new Lean Factory covers 11,000 m2 and has the goal of increasing production efficiency and volumes in order to achieve the set growth targets. With a
- FDA Warns Consumers Not to Purchase or Use 27 Brands of Eye Dropshttps://modernod.com/news/fda-warns-consumers-not-to-purchase-or-use-26-brands-of-eye-drops/2481919/In its most wide-reaching warning yet, the FDA advised consumers not to purchase and to immediately stop using 27 ov
- Vision Innovation Partners Names Chris Moore as CEOhttps://modernod.com/news/vision-innovation-partners-names-chris-moore-as-ceo/2481914/Vision Innovation Partners (VIP), a Mid-Atlantic eye care platform with nearly 70 locations, announced the promotion of existing board member and current President, Chris Moore, to Chief Executive Officer. Former CEO and founder Mike Dunn is now serving as Executive Vice President of Business Dev